PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Last Patient Enrolled for Planned Unblinded Interim Analysis in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 Unblinded Interim Analysis Outcome Expected Later this Quarter SHIELD II Enrollment Completion Expected in December 2024 with T op- L ine Results Anticipated in First Quarter of 2025